nivolumab,ipilimumab
bms
['thoracic', 'mesothelioma', 'scienceatbms', 'bms']
don t miss late-breaking data at #esmo22: 4-year landmark survival data from a phase 3 trial of first-line dual #immunotherapy in #mesothelioma. tune in live or virtually at 15:15 (cest); #thoraciccancers 
Official Bristol Myers Squibb Twitter handle for science. Connecting researchers, scientists and healthcare professionals through science; guidelines below: